Close
Help




JOURNAL

Clinical Medicine Insights: Therapeutics

A Review of Topical Imiquimod in the Management of Basal Cell Carcinoma, Actinic Keratoses, and Other Skin Lesions

Submit a Paper


Clinical Medicine Insights: Therapeutics 2009:1 1557-1575

Review

Published on 03 Nov 2009


Further metadata provided in PDF



Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Insights: Therapeutics

Abstract

Imiquimod (trade name Aldara™) is a small molecule of the imidazoquinoline family, a group of nucleoside analogs that were first synthesized as potential antiviral agents. It has since been discovered to activate both innate and adaptive immunity, as well as apoptosis. Clinically, it has been approved for three indications thus far: external genital warts, actinic keratosis, and superficial basal cell carcinoma. In addition to these applications, a number of off-label uses have been reported in the literature. In this review, we summarize and discuss the literature describing imiquimod’s mechanism of action, its approved and off-label clinical uses, and its safety and tolerability.



Downloads

PDF  (672.64 KB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)


Sharing


What Your Colleagues Say About Clinical Medicine Insights: Therapeutics
It is my pleasure to confirm that we had a very pleasant experience by publishing our article in Clinical Medicine Insights: Therapeutics.  The review process was highly efficient and the reviewers' comments useful and constructive.  I am sure that this is the kind of publication needed by the scientific community.  I am looking forward future collaborations.
Dr Federico Navarro Sarabia (University Hospital Virgen Macarena, Sevilla, Spain)
More Testimonials

Quick Links


New article and journal news notification services
Email Alerts RSS Feeds
Facebook Google+ Twitter
Pinterest Tumblr YouTube